Valls Nicolás, Villablanca Nicolás, González Roberto, Ramirez María Soledad, Almeida Carla, Lopez Julio
Anesthesiology, Anesthesia Unit, National Cancer Institute, Santiago, CHL.
Anesthesiology and Perioperative Medicine, University of Chile Clinical Hospital, Santiago, CHL.
Cureus. 2024 Nov 27;16(11):e74606. doi: 10.7759/cureus.74606. eCollection 2024 Nov.
Totally implantable venous access devices (TIVADs) are widely used in oncology patients to facilitate central venous access. Although they offer benefits, TIVADs can be associated with complications.
This retrospective cohort study included all oncology patients 18 years or older who underwent TIVAD implantation between September 2015 and October 2019. Data were obtained from clinical records at the National Cancer Institute.
A total of 556 TIVAD implantations were performed in cancer patients throughout the study period. The success rate for the first attempts was 91% (506/556). Infectious complications were documented in six patients (1.1%), while non-infectious complications manifested in less than 1% of cases, with hematoma at the insertion site being the most common. Additionally, catheter thrombosis was identified in three asymptomatic patients (0.5%).
The implantation of TIVADs by anesthesiologists in cancer patients at the National Cancer Institute was predominantly successful and safe, exhibiting a low complication rate. The findings reinforce the efficacy and safety of the employed technique, exceeding the outcomes reported in existing medical literature.
完全植入式静脉通路装置（TIVADs）广泛应用于肿瘤患者，以方便中心静脉通路。尽管它们有诸多益处，但TIVADs可能会引发并发症。
这项回顾性队列研究纳入了2015年9月至2019年10月期间接受TIVAD植入的所有18岁及以上的肿瘤患者。数据来自国家癌症研究所的临床记录。
在整个研究期间，共对癌症患者进行了556次TIVAD植入。首次尝试的成功率为91%（506/556）。6名患者（1.1%）出现感染性并发症，而非感染性并发症的发生率不到1%，其中插入部位血肿最为常见。此外，在3名无症状患者中发现了导管血栓形成（0.5%）。
国家癌症研究所的麻醉医生为癌症患者植入TIVADs大多成功且安全，并发症发生率较低。这些发现强化了所采用技术的有效性和安全性，优于现有医学文献报道的结果。
